Sign in
Not yet taking people in United StatesPhase 2

SM-1 sleep drug tested for short-term trouble sleeping after a time shift

Tests SM-1 against another medicine in adults with occasional transient insomnia.

Key facts

Who runs it
Sequential Medicine Ltd
Where
New York, United StatesSee the site
Trial code
Registry title
SM-1 vs. an Active Comparator in A Model of Transient Insomnia
Status
Not yet recruiting
Phase
Phase 2
People taking part
14 people, planned
Started
27 May 2020
Planned end
30 Jun 2020
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • SM-1
  • Active Comparator
Record updated
20 May 2020

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for healthy adults who sometimes had trouble falling or staying asleep but do not sleep badly now. They spend 1 night at a sleep center in each of 2 treatment periods.

Age
25 to 55 years
Sex
All sexes
Disease stage
Past occasional trouble falling or staying asleep, with no current sleep trouble and no long-term (chronic) insomnia. Regular bedtime between 21:00 and 24:00, with at least 7.5 and no more than 9.0 hours in bed nightly. Bedtime varies by no more than 2 hours over the week. Naps no more than once per week. BMI between 19 and 32 kg/m2.
Earlier treatment
You cannot join if you took any study drug, or diphenhydramine, zolpidem, lorazepam or similar drugs, within 30 days of screening. No prescription or over-the-counter medicines, herbal products or supplements are allowed, except vitamins, acetaminophen or hormonal birth control.
Biomarker or test result
Negative pregnancy tests for women who could become pregnant. Negative urine drug and alcohol tests. STOP-BANG score below 3 and Epworth Sleepiness Scale score of 10 or less.

Main reasons for not taking part

  • Sleep disorders such as chronic insomnia, sleep apnea, narcolepsy or restless legs
  • Serious physical or mental illness, cancer, diabetes, seizures or chronic pain
  • Blood pressure above 140/90 mm/Hg or heart rate above 100 BPM at screening
  • Pregnancy or breastfeeding, alcohol or drug abuse, or heavy smoking
  • Shift work, travel across more than three time zones, or any earlier night in a sleep laboratory

This trial only enrols healthy participants. The registry sentence this rests on: Good general health

The registry criteria, word for word

Show all 41 criteriaShow less

Who can take part

  • Age 25 and 55 years
  • Body mass index (BMI) between 19 and 32 kg/m2
  • Report previous history of occasional difficulty falling asleep or staying asleep, but not currently having difficulty sleeping
  • Regular, habitual bedtime between 21:00 and 24:00, routinely spend at least 7.5 and no more than 9.0 hours in bed nightly and a bedtime that does not vary by more than 2 hours over the course of the week
  • Good general health
  • Females of childbearing potential must be using an acceptable method of contraception, have a negative serum pregnancy test at screening and have a negative urine pregnancy test before randomization and prior to each Treatment Period
  • Female subjects who have been surgically sterilized are eligible if they have a negative serum pregnancy test at screening and negative urine pregnancy test at check-in or are post-menopausal or have had a complete hysterectomy
  • Male subjects must use an acceptable method of contraception during the course of the study and for the 90 days following the last dose of study medication
  • Obtain signed informed consent
  • Able to stay in the clinical research unit for 1 overnight stay during each treatment period
  • No alcohol on check-in days
  • Refrain from the use of alcohol and from napping on site check-in days
  • A recent history of napping of no more than once per week

Who cannot take part

  • Clinically significant, acute illness within 14 days prior to screening
  • Subject has homicidal ideation/intent, per the investigator's clinical judgment, or has suicidal ideation with some intent to act within 6 months prior to the start of the screening phase, per the investigator's clinical judgment or based on the C-SSRS
  • Positive urine drug screen
  • Recent history or current evidence of alcohol or drug abuse
  • Use of restricted concomitant medications, any prescription drug, OTC medication, grapefruit, grapefruit juice, herbal preparation or food supplement, excluding vitamins, acetaminophen or hormonal contraceptives
  • Exposure to any investigational drug or to diphenhydramine, zolpidem or lorazepam or other drugs of the same pharmaceutical classes within 30 days of screening 30. Positive alcohol or drug test
  • Clinically significant, unstable medical illness
  • Evidence or history of clinically significant allergic hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic or neurological disease
  • History of cancer or diabetes
  • Heart rate > 100 beats per minute (BPM) at screening
  • Clinically significant psychiatric illness, including chronic psychiatric illness or the history or presence of any Axis I condition
  • Lifetime history of seizure disorder or serious head injury
  • Clinically significant sleep disorder, including chronic insomnia, sleep apnea, narcolepsy, parasomnia, restless leg syndrome or circadian rhythm disorder
  • Any condition that may affect drug absorption
  • History of allergies, or known sensitivity, hypersensitivity, or adverse reaction to any drug similar to diphenhydramine, zolpidem or lorazepam
  • Slept in a sleep laboratory at any time prior to Screening
  • Any clinically significant abnormal finding on physical examination, vital signs or clinical laboratory tests,
  • Positive serum or urine pregnancy test
  • A sitting blood pressure > 140/90 millimeters mercury (mm/Hg) at screening
  • History or presence of chronic pain
  • STOP-BANG sleep apnea questionnaire >/= to 3 at Screening
  • Epworth Sleepiness Scale (ESS) score >10 at screening
  • Travel across more than three time zones or shift worker
  • Pregnant or lactating females
  • Regular consumption of "large amounts" of xanthine-containing substances (i.e., [equivalent to approximately 2 - 3 cups of regular coffee] or equivalent amounts of xanthine-containing substances)
  • Usual consumption of more than 14 units of alcohol per week
  • Use of more than 10 cigarettes or equivalent per day of any product containing nicotine or routinely smokes during sleep period
  • Stopped smoking or in a smoking cessation program within 90 days of screening

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 25 and 55 years old?

Where in United States

  • Clinilabs Drug Development CorporationNew York, United StatesContact: Clinilabs Drug Development CorporationNot yet recruiting

About the trial

What the trial wants to find out

The purpose of this study is to investigate the effectiveness, safety and tolerability of a combination drug product (SM-1) containing diphenhydramine, zolpidem and lorazepam, in adult participants who sometimes have difficulty in falling asleep or staying asleep, but who do not have chronic insomnia. Participants will receive SM-1 or a combination of diphenhydramine and lorazepam during 2 one-night stays at a sleep center.

The 2 groups in the trial

  • Active Comparator: 2-Drug CombinationExisting treatment, for comparison

    50 mg diphenhydramine and 0.5 mg lorazepam

    Treatment: Active Comparator

  • Active Treatment: SM-1 3-Drug CombinationTreatment being tested

    3-drug combination product containing 50 mg diphenhydramine, 5 mg zolpidem and 0.5 mg lorazepam

    Treatment: SM-1

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
A Randomized, Double-Blind, Single-Dose, 2-Way Cross-Over Study to Assess the Pharmacodynamic Effects of SM-1 vs. Active Comparator in a 3-Hour Phase Advance Model of Transient Insomnia
Plain-language title
SM-1 sleep drug tested for short-term trouble sleeping after a time shiftGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 14 November 2026.
Fit questions
Built from NCT04396327, who can take part
Record updated
20 May 2020